Abstract:Objective: Ewing sarcoma is an aggressive cancer most frequently diagnosed in adolescents and young adults. Currently, there is a limited understanding of the immunobiology of Ewing sarcoma, including limited pre-clinical studies of immunotherapeutic interventions. This, in part, is due to the historical lack of an immuno-competent murine model. Here, we utilize an immunocompetent, humanized mouse model to investigate the Ewing tumor immune microenvironment. Specifically, we sought to determine the transcriptional differences that occur when comparing human Ewing tumors established in a humanized backdrop versus those developed in an NSG (immuno-deficient) model. Methods: Human Ewing cell lines (A673, TC32, TC71) and PDX (PSaRC219) were injected orthotopically into humanized or NSG mice. After ~3 weeks, bulk RNA sequencing was performed on tumors utilizing an Illumina Next Generation Sequencer. Tumor single-cell suspensions underwent immunophenotyping by flow cytometry (CyTek Aurora) for the following human markers: CD45, CD3, CD4, CD8, CD56, CD14, CD16, etc.. Peripheral blood was collected, PBMCs isolated, and immunophenotyping was again performed to determine peripheral blood immune cell populations. Results: Ewing tumors established in humanized mice demonstrate infiltration of human CD45+ cells as well as immune cell sub-populations (CD3+, CD14+, CD56+ cells). Bulk RNA sequencing analysis utilizing unsupervised hierarchal clustering revealed that the transcriptional profile of Ewing tumors generated in humanized vs NSG mice cluster distinctly. Pathway analysis of differentially expressed genes (p <0.05) in Ewing tumors developed in humanized versus NSG mice demonstrates upregulation of pathways including extracellular matrix remodeling, collagen biosynthesis, and Wnt signaling. Notably, transcripts known to be specific to TGFBeta-dependent signaling in Ewing tumors are upregulated in the immune competent model, including TGFB1, FBLN5, and COLEC12. Conclusion: This work demonstrates the Ewing tumor transcriptional remodeling that occurs when tumors are developed in an immunocompetent in vivo backdrop. Upregulation of several pro-metastatic pathways were noted. Ongoing work focuses on testing drug response differences between Ewing tumors developed in humanized versus NSG backdrops and pursuing immunocompetent Ewing models as a component of preclinical agent testing. Citation Format: Jessica D. Daley, Elina Mukherjee, A Carolina Tufino, Riyue Bao, Kelly M. Bailey. Transcriptional reprogramming of Ewing tumors: gains and losses noted when utilizing immunocompetent in vivo models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2641.

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment

YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells

Abstract 1087: Synergistic mechanisms against pediatric bone sarcoma models: Trabectedin enhances oncolytic virotherapy intratumoral spread and antitumor immune activation

Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy

Immunocompetent murine model of Ewing sarcoma reveals role for TGFβ inhibition to enhance immune infiltrates in Ewing tumors during radiation

Abstract 2641: Transcriptional reprogramming of Ewing tumors: gains and losses noted when utilizing immunocompetent in vivo models

MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo

Abstract 1080: Using genome-wide CRISPR screening to develop novel combination therapies for high-risk Ewing's sarcoma

Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies

Role of immunotherapy in Ewing sarcoma

Oncolytic virotherapy stimulates anti‐tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases

Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma

Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

Somatic gene delivery for flexible modeling of high-risk sarcoma

Phase 1 Clinical Trial to Assess Safety and Efficacy of NY-ESO-1-specific TCR T Cells in HLA-A∗02:01 Patients with Advanced Soft Tissue Sarcoma.

Enhancing standard of care chemotherapy efficacy using DNA-dependent protein kinase (DNA-PK) inhibition in preclinical models of Ewing sarcoma